# Oral Bioavailability of Two Solid Formulations of GLPG0634

> **NCT01915667** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 200 mg GLPG0634 as capsules, fasted
- **DRUG:** 200 mg GLPG0634 as tablets, fasted
- **DRUG:** 200 mg GLPG0634 as tablets, fed

## Key facts

- **NCT ID:** NCT01915667
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01915667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01915667, "Oral Bioavailability of Two Solid Formulations of GLPG0634". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01915667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*